Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: BDX

Becton, Dickinson and Company

Healthcare | Medical - Instruments & Supplies
$158.08 +11.59 (+7.91%) as of 2026-07-14 09:13 UTC
Market Cap$57.3B
Volume1.66M
EPS (TTM)$5.82

Becton, Dickinson and Company (NYSE: BDX) is a $57.3B medical - instruments & supplies company trading at $158.08 (+7.9% today) — 27.2× trailing earnings, yielding 2.62%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 09:13 UTC.

52-Week Range
Low $145.15High $159.95

What Becton, Dickinson and Company does

The company sells medical devices and diagnostic products to healthcare providers, researchers at pharmaceutical and biotechnology companies, academic institutions, and government laboratories. Its business faces pricing pressure from government cost-control initiatives globally, including competitive bidding programs and price regulation mechanisms that have reduced revenues in certain countries. Revenue depends significantly on research and development spending by customers and government funding levels, which have been unpredictable and subject to reduction.

Summarized from Becton, Dickinson and Company’s SEC filings · Read the filing ↗

Key facts
Quote
Price$158.08
Change (1D)+11.59 (+7.91%)
Market cap$57.3B
Volume1.66M shares
52-week range$145.15 – $159.95
Valuation
P/E (TTM)27.16×
EV/EBITDA15.00×
EPS (TTM)$5.82
Dividend yield2.62%
Price/book2.26×
Return on equity6.61%
Debt/equity0.76
Returns
52-week return+8.9%
Revenue, margins & earnings
FY2021 Net income: $2.09BFY2021 Operating costs: $16.9B$19.1BFY2021FY2022 Net income: $1.78BFY2022 Taxes & interest: $503MFY2022 Operating costs: $16.6B$18.9BFY2022FY2023 Net income: $1.48BFY2023 Taxes & interest: $627MFY2023 Operating costs: $17.3B$19.4BFY2023FY2024 Net income: $1.71BFY2024 Taxes & interest: $692MFY2024 Operating costs: $17.8B$20.2BFY2024FY2025 Net income: $1.68BFY2025 Taxes & interest: $901MFY2025 Operating costs: $19.3B$21.8BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-06
  • 2026-07-06Muhsin BilalEVP & President Connected CareA14,342—
  • 2026-07-06Muhsin BilalEVP & President Connected CareF-1,935—
  • 2026-06-26Feld MichaelEVP, Chief Revenue OfficerSELL-75$11.5K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
No 13F filings reference BDX in the last quarter.
Source: SEC EDGAR · Last checked 2026-07-14
Company news View all →
Questions this page answers

What does Becton, Dickinson and Company do?

The company sells medical devices and diagnostic products to healthcare providers, researchers at pharmaceutical and biotechnology companies, academic institutions, and government laboratories.

What is BDX's valuation?

BDX trades at $158.08, 27.16× trailing earnings, 15.00× EV/EBITDA, as of 2026-07-14. It carries a 2.62% dividend yield.

When did BDX last file with the SEC?

Becton, Dickinson and Company's most recent SEC filing on record is a 8-K filed 2026-05-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 09:13 UTC. This page is also available as JSON at /api/data?ticker=BDX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BDX and 3,500+ tickers.

Create a free account — keep BDX
For your agent
GET /api/data?ticker=BDX

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt